Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsAntiviral drugs for viruses other than human immunodeficiency virusThe Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ TransplantationValganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacyChanging impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran.Manipulation of Viral MicroRNAs as a Potential Antiviral Strategy for the Treatment of Cytomegalovirus Infection.New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsManagement of cytomegalovirus infection and disease in liver transplant recipients.Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients.Advances in gene therapy for malignant melanoma.Prevention of cytomegalovirus disease in recipients of solid-organ transplants.Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.Epidemiology of infections after solid-organ transplantation.Posttransplant microbiological surveillance.Management of cytomegalovirus infection and disease after solid-organ transplantation.Infection in solid organ transplantation.Prevention of infections in solid organ transplant recipients.Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Current concepts on cytomegalovirus infection after liver transplantationValganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipientsLate hepatic allograft dysfunction.Prophylaxis and treatment of gastrointestinal complications following transplantation.Liver transplantation in the UK.Human cytomegalovirus terminase as a target for antiviral chemotherapy.Varicella zoster virus (VZV) in solid organ transplant recipients.Beta-herpesvirus challenges in the transplant recipient.Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir.Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.Human embryonic stem cells: a potential source for cellular therapy.Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction.Pulmonary complications of solid organ and hematopoietic stem cell transplantation.Management of opportunistic infections in solid-organ transplantation.Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults.Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
P2860
Q24200697-06D51AB2-A24A-4174-8CC5-17994C45BB6CQ24200991-5DD73252-30C9-4142-86F9-FA0DC32B8729Q24243124-6BFFA132-EE99-44CA-9EFB-D6624F1B87DFQ24244606-33981F90-9128-448A-BAA9-17D903B55C48Q24635330-105D8759-72DF-42E6-A1B5-2531C550B4CBQ28085440-FEF711B4-1E2D-42F6-AE7C-3EF9FC69C1B1Q28475480-B9F80959-AE34-4FBA-965E-816764727A27Q33218675-A0D0DB75-9F29-4378-86B1-12B9FBC5FA35Q33624126-0B889D8E-01D5-49A6-A103-6AD7A864A819Q33753996-0AECE0FE-9691-4978-BF4D-6BE9BC2ECC9DQ33812425-E85FEC66-8F97-45D9-BABF-214554AD042AQ33845124-C582EFD2-DEDB-4B87-A6F4-099C14DC8840Q33969461-DE2D8E5A-E9F6-45BB-83DA-0C997C9ABA67Q34119859-800A6FD8-F4CF-453E-BB31-C6BF5ADA1F97Q34142019-9BBA3EC1-08A5-42CF-9A6B-F7352FB04805Q34191785-F3CB6AF6-1CD4-4F84-BEA8-3D71259495C5Q34191791-70D90955-6C75-4790-9A9C-032008C1CBEAQ34271651-C81A7537-6EDE-47A0-A2C3-20E2E589442CQ34271669-FFF1EDC6-08AC-4413-A9D5-03793D4A1757Q34271684-91B492BC-C234-40A2-8AB9-81C4BA12CC9AQ34294779-F094E1FD-C9DA-4140-A819-07D296BC388DQ34294796-81E55497-D849-42E7-B3A8-247380C91F1CQ34294806-52CD7059-C83C-4E8A-B4C7-14D97C167467Q34294851-1AF8AAFF-C529-451E-9B1B-AA1F3848F678Q34390310-43F42D20-D541-402F-8178-2D8FF95580B6Q34413103-63924AE8-B182-429B-8785-24042B72EAAEQ34426400-BFE16433-6A42-4339-B87C-9FAAD83E3C4BQ34485493-22F27D76-F96D-4E0F-B928-9A4AF23467B1Q34512132-69CEABC8-5070-4042-B938-472BBC05860FQ34580776-D54385AD-B8FE-4782-8F4E-C5BF4EA19886Q34615689-008447E5-6483-40FF-BC8B-6DA646CA87CCQ34918418-A9FE498E-6381-4BF4-91B6-FBA8129FE58EQ34918468-CBDDFD95-40F5-4BA7-A22F-DD96AA7CA2D2Q35598906-6424CBB1-26B5-48A2-A56E-05BFD26D8D78Q35661046-0075CF47-6244-4259-BE4A-4468B7ACA765Q35732096-568D08B1-E92E-4ED7-A296-3631C5C379A8Q35740698-23CEA264-252B-4703-9EB1-2886380BED3EQ35841369-C53ACC2D-B4BF-463D-91F0-EC0187FF17DDQ35859879-CE1FBB06-0380-451B-8A3C-CB29FD9D76F8Q35871893-8DA28DDF-0718-4BDA-81C8-9795040FF008
P2860
Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Randomised trial of efficacy a ...... ation Study Group [corrected].
@en
Randomised trial of efficacy a ...... ation Study Group [corrected].
@nl
type
label
Randomised trial of efficacy a ...... ation Study Group [corrected].
@en
Randomised trial of efficacy a ...... ation Study Group [corrected].
@nl
prefLabel
Randomised trial of efficacy a ...... ation Study Group [corrected].
@en
Randomised trial of efficacy a ...... ation Study Group [corrected].
@nl
P2093
P1433
P1476
Randomised trial of efficacy a ...... ation Study Group [corrected].
@en
P2093
C A Robinson
G J Valdecasas
M D Pescovitz
P304
P356
10.1016/S0140-6736(97)05535-9
P407
P577
1997-12-01T00:00:00Z